“Fed Proof” Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

James Edgemond Biography and Net Worth

CFO of United Therapeutics

Mr. Edgemond joined United Therapeutics in January 2013 as Treasurer and Vice President, Strategic Financial Planning. Mr. Edgemond was promoted to Chief Financial Officer and Treasurer in March 2015.

Prior to joining United Therapeutics, he was Vice President, Corporate Controller, and Treasurer of Clark Construction Group from 2008 through January 2013. He also served in a variety of roles at The Corporate Executive Board Company from 1998 to 2008, including as Executive Director, Finance from 2005 to 2008. He began his career as a public accountant at KPMG Peat Marwick LLP, from 1990 through 1998, where he served in a variety of roles, including as a Senior Manager prior to his departure.

What is James Edgemond's net worth?: The estimated net worth of James Edgemond is at least $2.54 million as of October 28th, 2024. Mr. Edgemond owns 6,978 shares of United Therapeutics stock worth more than $2,537,131 as of November 20th. This net worth approximation does not reflect any other assets that Mr. Edgemond may own. Additionally, Mr. Edgemond receives an annual salary of $2,150,000.00 as CFO at United Therapeutics. Learn More about James Edgemond's net worth.
How old is James Edgemond?: Mr. Edgemond is currently 56 years old. There are 3 older executives and no younger executives at United Therapeutics. The oldest executive at United Therapeutics is Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D., Founder, Chairman & CEO, who is 69 years old. Learn More on James Edgemond's age.
What is James Edgemond's salary?: As the CFO of United Therapeutics Co., Mr. Edgemond earns $2,150,000.00 per year. There are 3 executives that earn more than Mr. Edgemond. The highest earning executive at United Therapeutics is Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D., Founder, Chairman & CEO, who commands a salary of $5,660,000.00 per year. Learn More on James Edgemond's salary.
How do I contact James Edgemond?: The corporate mailing address for Mr. Edgemond and other United Therapeutics executives is 1040 SPRING ST, SILVER SPRING MD, 20910. United Therapeutics can also be reached via phone at (301) 608-9292 and via email at [email protected]. Learn More on James Edgemond's contact information.
Has James Edgemond been buying or selling shares of United Therapeutics?: In the last ninety days, James Edgemond has sold $11,130,011.90 of United Therapeutics stock. Most recently, James Edgemond sold 7,800 shares of the business's stock in a transaction on Monday, October 28th. The shares were sold at an average price of $350.00, for a transaction totalling $2,730,000.00. Following the completion of the sale, the chief financial officer now directly owns 6,978 shares of the company's stock, valued at $2,442,300. Learn More on James Edgemond's trading history.
Who are United Therapeutics' active insiders?: United Therapeutics' insider roster includes Michael Benkowitz (COO), Christopher Causey (Director), Raymond Dwek (Director), James Edgemond (CFO), Paul Mahon (EVP), Nilda Mesa (Director), Judy Olian (Director), Christopher Patusky (Director), Martine Rothblatt (CEO), and Louis Sullivan (Director). Learn More on United Therapeutics' active insiders.
Are insiders buying or selling shares of United Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 79 times. They sold a total of 430,475 shares worth more than $126,938,624.54. The most recent insider tranaction occured on November, 11th when COO Michael Benkowitz sold 15,000 shares worth more than $6,109,800.00. Insiders at United Therapeutics own 11.9% of the company. Learn More about insider trades at United Therapeutics.
Information on this page was last updated on 11/11/2024.

James Edgemond Insider Trading History at United Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/28/2024	Sell	7,800	$350.00	$2,730,000.00	6,978
10/21/2024	Sell	7,782	$366.99	$2,855,916.18	6,426
10/14/2024	Sell	7,792	$355.88	$2,773,016.96	5,884
10/7/2024	Sell	7,794	$355.54	$2,771,078.76	5,344
9/30/2024	Sell	7,792	$358.62	$2,794,367.04	4,802
9/23/2024	Sell	7,796	$354.04	$2,760,095.84	4,264
9/9/2024	Sell	7,802	$345.41	$2,694,888.82	3,210
9/3/2024	Sell	7,785	$362.37	$2,821,050.45	2,615

James Edgemond Buying and Selling Activity at United Therapeutics

United Therapeutics Company Overview

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Today's Range

Now: $364.33

$359.40

$365.67

50 Day Range

MA: $363.86

$339.12

$410.00

2 Week Range

Now: $364.33

$208.62

$417.82

Volume

199,252 shs

Average Volume

461,020 shs

Market Capitalization

$16.27 billion

P/E Ratio

16.00

Dividend Yield

N/A

Beta

0.56

“Fed Proof” Your Bank Account with THESE 4 Simple Steps

From Weiss Ratings | Ad

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

James Edgemond Biography and Net Worth

What is James Edgemond's net worth?

How old is James Edgemond?

What is James Edgemond's salary?

How do I contact James Edgemond?

Has James Edgemond been buying or selling shares of United Therapeutics?

Who are United Therapeutics' active insiders?

Are insiders buying or selling shares of United Therapeutics?